Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

← catalyst calendar

NCT05462717 · readout in 224 d

Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

222estimated

Sites

Countries

Australia, Czechia, France +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-09-19

actual

When the study began enrolling

Primary completion

2027-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-09-30

estimated

The whole study's end, after follow-up

First posted

2022-07-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma
Advanced Solid Tumor

Intervention

Drug: RMC-6291

Primary outcomes

what the primary-completion date above is the date OF

Adverse events

measured up to 3 years

Dose Limiting Toxicities

measured The first 21 days (i.e. Cycle 1)

Publications

PMID 37590355 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed